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Abstract
Background:  Epidemiologic studies have suggested that hypertriglyceridemia and insulin resistance are related to the
development of colon cancer. Nuclear peroxisome proliferator-activated receptors (PPAR), which play a central role in lipid
and glucose metabolism, had been hypothesized as being involved in colon cancerogenesis. In animal studies the lipid-lowering
PPAR ligand bezafibrate suppressed colonic tumors. However, the effect of bezafibrate on colon cancer development in humans
is unknown. Therefore, we proposed to investigate a possible preventive effect of bezafibrate on the development of colon
cancer in patients with coronary artery disease during a 6-year follow-up.
Methods: Our population included 3011 patients without any cancer diagnosis who were enrolled in the randomized, double
blind Bezafibrate Infarction Prevention (BIP) Study. The patients received either 400 mg of bezafibrate retard (1506 patients) or
placebo (1505 patients) once a day. Cancer incidence data were obtained by matching a subject's identification numbers with
the National Cancer Registry. Each matched record was checked for correct identification.
Results: Development of new cancer (all types) was recorded in 177 patients: in 79 (5.25%) patients from the bezafibrate group
vs. 98 (6.51%) from the placebo group. Development of colon cancer was recorded in 25 patients: in 8 (0.53%) patients from
the bezafibrate group vs. 17 (1.13%) from the placebo group, (Fisher's exact test: one side p = 0.05; two side p = 0.07).
A difference in the incidence of cancer was only detectable after a 4 year lag and progressively increased with continued follow-
up. On multivariable analysis the colon cancer risk in patients who received bezafibrate tended to be lower with a hazard ratio
of 0.47 and 95% confidence interval 0.2–1.1.
Conclusion: Our data, derived from patients with coronary artery disease, support the hypothesis regarding a possible
preventive effect of bezafibrate on the development of colon cancer.
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Background
Colon cancer is one of the leading forms of malignancy in
the developed countries. Epidemiologic and animal stud-
ies have suggested that risk factors for coronary artery dis-
ease like insulin resistance and dyslipidemia are probably
related to the development of colon cancer [1-7]. Particu-
larly, nuclear peroxisome proliferator-activated receptors
(PPAR), mainly alpha and gamma, which play a central
role in lipid and glucose metabolism, had been hypothe-
sized as being involved in colon cancerogenesis [8-12].
Furthermore, synthetic PPAR ligands (glitazones and bez-
afibrate) with proven beneficial effects on insulin resist-
ance and triglyceride levels had been proposed to be
candidates as tumor preventive agents [12-14].
While dietary administration of pan-PPAR ligand bezafi-
brate has been demonstrated to suppress the development
of colonic tumors in rodents [12-14], its effect on colon
cancer development in humans is unknown. We therefore
sought to investigate a potential preventive effect of bezaf-
ibrate on the development of colon cancer in patients
with coronary artery disease enrolled in the randomized,
double blind Bezafibrate Infarction Prevention (BIP)
Study.
Methods
The major inclusion and exclusion criteria for the BIP
study, as well as the ethical guidelines, have been previ-
ously reported [15]. In brief, inclusion criteria for men
and women comprised: age 45–74 years, history of myo-
cardial infarction no less than 6 months and not more
than 5 years prior to enrollment into the study and/or sta-
ble angina pectoris. The major exclusion criteria for the
BIP study were: malignant diseases, permanent pace-
maker implantation, cerebrovascular disease, chronic
hepatic or renal disease, peripheral vascular disease, estro-
gen replacement therapy, insulin dependent diabetes mel-
litus and current use of a lipid modifying drug.
There were 3090 patients who were included in the BIP
study after screening. Patients in whom a diagnosis of can-
cer had been made after screening but before the launch
of the study medication as well as patients with unknown
vital status were excluded from this analysis. Thus, the
final study sample for our study comprised 3011 patients.
The patients received either 400 mg of bezafibrate retard
or placebo once a day. Patients continued their prescribed
medications for cardiac and other conditions except lipid
lowering drugs. The primary endpoint of the BIP study
was fatal or non-fatal MI or sudden death (combined
major cardiovascular events).
Cancer incidence data were obtained by matching a sub-
ject's personal identification number (PID) with the Israel
National Cancer Registry (INCR). Each matched record
was checked for correct identification.
The detailed description of INCR has been published pre-
viously [16]. In summary, the INCR is a population-based
central tumor registry established in 1960 and since 1982
reporting to the registry is mandatory [17]. All medical
facilities, both public and private and pathology laborato-
ries that are diagnosing or treating cancer patients send a
copy of their medical summary which contains tumor
characteristics to the Registry. The INCR also collects data
on cancer deaths from District Health Authorities and the
Central Population Registry. In Israel, all demographic
data are stored in the Central Population Registry in
accordance with PID. The INCR is linked to this Registry
and each cancer patient's personal data are then retrieved
and validated. The last audit of data completeness con-
cluded that registration was above 95% [18].
The mean follow-up period of the BIP study was 6.2 ± 0.8,
range 4.7 to 7.6 years. The trial was conducted independ-
ently of the sponsor (Boehringer Mannheim GmbH,
which is now part of F. Hoffmann-La Roche, Ltd), and it
was approved by the Helsinki Committees of each center
and the central national Helsinki Committee.
Data were analyzed using the SAS software, version 8.2
(SAS Institute Inc., Cary, NC, USA). Continuous variables
at baseline were presented as mean values ± standard devi-
ation (SD). Comparisons between groups were made
using chi-square tests for discrete variables and Student t-
test or Wilcoxon rank sum test for continuous variables. A
p-value of less than 0.05 was considered as statistically sig-
nificant.
Kaplan-Meier curves were produced using the LIFETEST
procedure. The log-rank test was used for comparing the
curves.
Multivariable analysis of the incidence of colon cancer
was performed using the Cox proportional hazard model
(PHREG procedure) to account for differing lengths of fol-
low-up and correlation with covariates. Hazard ratio (HR)
and 95% confidence interval (CI) for new colon cancer
was calculated. Variables included in the models were age,
gender, total cholesterol, ln transformed triglycerides,
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Patients in the placebo and bezafibrate groups were well
balanced in terms of clinical and laboratory baseline char-
acteristics (Table 1). The study groups were similar in
regard to age, gender and the prevalence of the most rele-
vant cardiovascular diseases and risk factors (a myocardial
infarction in the past, hypertension, diabetes, heart fail-
ure, anginal syndrome). The majority of the patients in all
groups were men who had sustained a myocardial infarc-
tion in the past. No significant differences between the
groups were found for all types of cholesterol, systolic and
diastolic blood pressure, heart rate, body mass index, fast-
ing glucose, triglycerides and fibrinogen levels. At base-
line, nitrates, calcium antagonists, beta blockers and
antiplatelet drugs (mainly aspirin) were the most com-
monly used medications. There were no significant differ-
ences between the groups in the proportion of patients
receiving other cardiovascular drugs.
Clinical outcomes
During the follow-up period, development of new cancer
(all types) was recorded in 177 patients: in 79 (5.25%)
patients from the bezafibrate group vs. 98 (6.51%) from
the placebo group (p = 0.14). Development of new colon
cancer was recorded in 25 patients (Figure 1): in 8
(0.53%) patients from the bezafibrate group vs. 17
(1.13%) from the placebo group, (Fisher's exact test: one
side p = 0.05; two side p = 0.07).
Kaplan-Meier curves of colon cancer incidence (in accord-
ance with the time of diagnosis) for the two study groups
are presented in Figure 2. The incidence rate of patients on
placebo tended to be higher than in their bezafibrate
treated counterparts, (p log-rank = 0.07). A difference in
the incidence of cancer was only detectable after a 4 year
lag and progressively increased with continued follow-up.
On multivariable analysis the colon cancer risk in patients
received bezafibrate tended to be lower with a hazard
ratio of 0.47 and 95% confidence interval 0.2–1.1.
Discussion
The main novel finding in this post hoc analysis of the BIP
study, which was randomized and double blind in design,
is a possible preventive effect of bezafibrate on the devel-
opment of colon cancer in humans. The study hypothesis
is supported not only by the magnitude of colon cancer
risk reduction in patients treated by bezafibrate (53%),
but, more importantly by the time-course of the Kaplan-
Meier curves: The 4 year lag in the occurrence of detectable
Table 1: Baseline characteristics of the study population.
Characteristics Bezafibrate (n = 1506) Placebo (n = 1505) p value
Age (years) 60.0 ± 6.8 60.0 ± 6.7 0.9
Body mass index (kg/m2) 26.7 ± 3.3 26.7 ± 3.3 0.7
Men (%) 1374(91) 1382 (92) 0.6
Past myocardial infarction (%) 1184 (79) 1163 (77) 0.3
Angina (%) 848 (56) 876 (58) 0.3
NYHA Class ≥2 (%) 45 (27) 47 (26) 0.9
Hypertension (%) 462 (31) 507 (34) 0.1
Current smokers 177 (12) 184 (12) 0.7
Systolic blood pressure (mmHg) 134 ± 18 133 ± 18 0.3
Diastolic blood pressure (mmHg) 81.1 ± 9.0 80.8 ± 9.1 0.4
Heart rate (beats/min) 70.1 ± 9.3 70.0 ± 9.3 0.8
Total cholesterol (mg/dl) 211 ± 17 213 ± 18 0.2
HDL-cholesterol (mg/dl) 34.5 ± 5.5 34.6 ± 5.5 0.7
LDL-cholesterol (mg/dl) 148 ± 16 149 ± 16 0.2
Triglycerides (mg/dl) 145 ± 51 145 ± 51 0.9
Fibrinogen (mg/dl) 350 ± 72 351 ± 74 0.7
New colon cancers (%) during follow-up; bezafibrate vs. pla- cebo (Fisher's exact test: one side p = 0.05; two side p =  0.07) Figure 1
New colon cancers (%) during follow-up; bezafibrate vs. pla-
cebo (Fisher's exact test: one side p = 0.05; two side p = 
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differences between groups, followed by a progressive dis-
parity in colon cancer incidence between patients on bez-
afibrate and patients on placebo are characteristic of a
biologic effect and thus support causality rather than
chance association.
Accumulating animal experimental, human laboratory
and epidemiologic data [6,10-14,19,20] support the
hypothesis linking triglyceride levels and insulin resist-
ance to the development of colon cancer. These facts
emphasize the potential for this cancer to become a pre-
ventable disease not only via screening and removal of
polyps but through relevant lifestyle changes and pharma-
cological interventions which can provide even more ave-
nues for prevention [19-25].
The fact that the incidence of insulin resistance has been
increasing in the Western world where colon cancer is the
second leading cause of cancer death makes the explora-
tion of the interrelationship of these conditions a subject
of high priority for public health.
The biological role of the peroxisome proliferator-acti-
vated receptors (PPARs) in various diseases, including
inflammation and cancer, has been highlighted recently
[8-14,26-28]. PPARs are members of the nuclear hormone
receptor family of ligand-activated transcription factors
that play a prominent role in the regulation of many met-
abolic processes. The alpha and gamma isoforms of PPAR
are important regulators in lipid and glucose metabolism,
cell differentiation and inflammatory response [29,30].
These data propose that PPAR alpha, beta/delta and
gamma may be associated with many aspects of colon
cancer development including insulin- and inflamma-
tion-related mechanisms.
The fibric acid derivative bezafibrate is the pan – (alpha,
beta/delta, gamma) PPAR activator with predominantly
PPAR alpha (as all fibrates) and beta/delta effects but also
with perceptible PPAR gamma properties [31-36]. The use
of bezafibrate is associated with triglyceride-lowering and
HDL-cholesterol raising effects resulting in decreased sys-
temic availability of fatty acid, diminished of fatty acid
uptake by muscle and improvement of insulin sensitiza-
tion [37,38]. These direct and indirect effects may have
contributed to the suppression of the development of
colonic tumors in rodents by bezafibrate [12-14].
Limitations of the study
Although development of new colon cancer in patients
randomized to bezafibrate was more than half as frequent
as in those randomized to placebo, the difference reached
only borderline statistical significance. The BIP study was
designed (both in terms of sample size and time of follow-
up) to detect the effect of the lipid-modifying agent bezaf-
ibrate on major cardiovascular events in coronary patients
at high risk, but had not an appropriate statistical power
to explore development of such a relatively low-incidence
disease as colon cancer. In addition, caution should be
used in interpreting our findings, as they were identified
in post-hoc analysis.
However, the detected pattern of the time course in the
differences between groups, suggesting a biologically
meaningful effect, is encouraging and supports the initia-
tion of a large prospective controlled trial in light of its
importance for public health.
Conclusion
The use of bezafibrate as lipid-modifying agent in patients
with coronary artery disease appears to be associated with
a reduced risk of colon cancer.
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